Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies
Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies
复制标题
DOI：
10.1345/aph.1d470
复制
发表时间：
2004-07-01
影响因子：
2.9
通讯作者：
Medina, PJ
中科院分区：
文献类型：
--
作者：
Zondor, SD;Medina, PJ
目的：回顾贝伐珠单抗的药理学、药代动力学和关键临床试验，强调其在结直肠癌中的应用。 数据来源：使用以下术语进行 PubMed/MEDLINE 检索（1966 年至 2004 年 4 月）：贝伐珠单抗、阿瓦斯汀、抗 VEGF、抗血管生成和结直肠癌。其他数据源包括会议摘要、已确定文章的参考书目以及来自制造商的信息。 研究选择和数据提取：从数据源中选择使用贝伐珠单抗治疗结直肠癌和其他恶性肿瘤的临床前和临床试验。本综述纳入了所有已发表的评估贝伐珠单抗治疗结直肠癌的随机临床试验。 数据综合：尽管化疗取得了进展，但目前针对转移性疾病的治疗选择只能为大多数患者提供暂时的益处。贝伐珠单抗是第一种被证明可以通过抑制血管生成为癌症患者带来益处的抗癌药物。贝伐珠单抗在治疗许多癌症（包括转移性结直肠癌）方面显示出显着的活性。当与基于氟尿嘧啶的化疗联合使用时，贝伐珠单抗可改善转移性结直肠癌患者的总体缓解率、进展时间和生存率。与贝伐单抗相关的常见毒性包括高血压、出血事件和血栓事件。 结论：尽管关于贝伐单抗有效性的临床知识有限，但早期数据表明，对于转移性癌症（包括结直肠癌）患者来说，它是一种有前景的药物，具有新颖的作用机制。
OBJECTIVE: To review the pharmacology, pharmacokinetics, and pivotal clinical trials for bevacizumab, emphasizing its use in colorectal cancer.DATA SOURCES: A PubMed/MEDLINE search was conducted (1966-April 2004) using the following terms: bevacizumab, Avastin, anti-VEGF, anti-angiogenesis, and colorectal cancer. Additional data sources included meeting abstracts, bibliographies from identified articles, and information from the manufacturer.STUDY SELECTION AND DATA EXTRACTION: Preclinical and clinical trials that used bevacizumab for the treatment of colorectal cancer and other malignancies were selected from the data sources. All published, randomized clinical trials evaluating bevacizumab in colorectal cancer were included in this review.DATA SYNTHESIS: Despite advances in chemotherapy, current therapeutic options for metastatic disease provide only temporary benefit for most patients. Bevacizumab is the first anti-cancer agent shown to provide benefit for patients with cancer by inhibiting angiogenesis. Bevacizumab has shown significant activity in the treatment of many cancers, including metastatic colorectal cancer. When used in combination with fluorouracil-based chemotherapy, bevacizumab improves overall response rates, time to progression, and survival in patients with metastatic colorectal cancer. Common toxicities associated with bevacizumab include hypertension, bleeding episodes, and thrombotic events.CONCLUSIONS: Although clinical knowledge on the effectiveness of bevacizumab is limited, early data indicate that it is a promising agent, with a novel mechanism of action, for patients with metastatic cancer, including colorectal cancer.